Review: Breaking From Bisphosphonates (Q38992765)

8 September 2017

1 reference

title

Review: Breaking From Bisphosphonates (English)

1 reference

8 September 2017

Margaret Seton

1

1 reference

8 September 2017

language of work or name

1 reference

27 October 2016

1 reference

8 September 2017

published in

Arthritis & Rheumatology

1 reference

8 September 2017

volume

69

1 reference

8 September 2017

issue

3

1 reference

8 September 2017

page(s)

494-498

1 reference

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

8 September 2017

cites work

1 reference

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

21 January 2018

1 reference

Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

Bisphosphonate drug holiday: who, when and how long

21 January 2018

1 reference

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

21 January 2018

1 reference

Ten years' experience with alendronate for osteoporosis in postmenopausal women

21 January 2018

1 reference

The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).

21 January 2018

1 reference

Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

Overdiagnosis of bone fragility in the quest to prevent hip fracture.

21 January 2018

1 reference

Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?

21 January 2018

1 reference

Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study

21 January 2018

1 reference

Bone density and bone turnover marker monitoring after discontinuation of alendronate therapy: an evidence-based decision to do less.

21 January 2018

1 reference

Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?

21 January 2018

1 reference

The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT).

21 January 2018

1 reference

Bisphosphonates for osteoporosis--where do we go from here?

21 January 2018

1 reference

Trends in hip fracture rates in Canada: an age-period-cohort analysis

21 January 2018

1 reference

Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011

21 January 2018

1 reference

Long-term safety of antiresorptive treatment: bone material, matrix and mineralization aspects

21 January 2018

1 reference

Risk of new vertebral fracture in the year following a fracture

21 January 2018

1 reference

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial

21 January 2018

1 reference

Functional integration of skeletal traits: an intraskeletal assessment of bone size, mineralization, and volume covariance

21 January 2018

1 reference

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro

21 January 2018

1 reference

Bone safety of long-term bisphosphonate treatment

21 January 2018

1 reference

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ART.39967

1 reference

8 September 2017

1 reference